A clarification was sought from the company regarding declining share prices on the back of USFDA observations. The shares of Aurobindo Pharma had slumped over 19 per cent and had hit its 52-week low of Rs 450 on Monday after the US health regulator issued seven observations. Read Also: Aurobindo Pharma Unit-7 gets 7 USFDA observations The United States Food and Drug Administration (USFDA) conducted a Current Good Manufacturing Practices (CGMP) inspection at the company's unit-7 manufacturing facility from September 19 to 27, Aurobindo Pharma had said in a BSE filing. The inspection ended with seven observations, it added. "We believe none of the observations is related to data integrity. The company is confident of addressing these issues within the stipulated timeline," Aurobindo Pharma said. Read Also: SEBI slaps fine of Rs 22 crore on Aurobindo Pharma, promoters for insider trading